Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 177 of the 179 references it cites were found in a registry or an index.

High-density lipoprotein revisited: biological functions and clinical relevance

Open access
von Eckardstein, Arnold, Nordestgaard, Børge G, Remaley, Alan T, Catapano, Alberico L · 2023 · European Heart Journal

Abstract

Previous interest in high-density lipoproteins (HDLs) focused on their possible protective role in atherosclerotic cardiovascular disease (ASCVD). Evidence from genetic studies and randomized trials, however, questioned that the inverse association of HDL-cholesterol (HDL-C) is causal. This review aims to provide an update on the role of HDL in health and disease, also beyond ASCVD. Through evolution from invertebrates, HDLs are the principal lipoproteins, while apolipoprotein B-containing lipoproteins first developed in vertebrates. HDLs transport cholesterol and other lipids between different cells like a reusable ferry, but serve many other functions including communication with cells and the inactivation of biohazards like bacterial lipopolysaccharides. These functions are exerted by entire HDL particles or distinct proteins or lipids carried by HDL rather than by its cholesterol cargo measured as HDL-C. Neither does HDL-C measurement reflect the efficiency of reverse cholesterol transport. Recent studies indicate that functional measures of HDL, notably cholesterol efflux capacity, numbers of HDL particles, or distinct HDL proteins are better predictors of ASCVD events than HDL-C. Low HDL-C levels are related observationally, but also genetically, to increased risks of infectious diseases, death during sepsis, diabetes mellitus, and chronic kidney disease. Additional, but only observational, data indicate associations of low HDL-C with various autoimmune diseases, and cancers, as well as all-cause mortality. Conversely, extremely high HDL-C levels are associated with an increased risk of age-related macular degeneration (also genetically), infectious disease, and all-cause mortality. HDL encompasses dynamic multimolecular and multifunctional lipoproteins that likely emerged during evolution to serve several physiological roles and prevent or heal pathologies beyond ASCVD. For any clinical exploitation of HDL, the indirect marker HDL-C must be replaced by direct biomarkers reflecting the causal role of HDL in the respective disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehac605

Cites

177 of 177 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical Abstract The great complexity of HDL. High-density lipoprotein (HDL) particles carry a large number of proteins and lipids, which contribute to define their compositional and functional complexity. HDLs exert multiple protective activities, essentially by three major mechanisms. HDLs, however, can lose their protective functions and even gain adverse functions in chronic diseases or during infections. U-shaped relationships between HDL-cholesterol (HDL-C) levels and several conditions have been reported, being both low and extremely high HDL-C levels associated with an increased risk of several pathologies and mortality. LCAT, lecithin:cholesterol acyltransferase; CETP, cholesteryl ester transfer protein; PONI, paraoxonase 1; S1P, sphingosine-1-phosphate; ASCVD, atherosclerotic cardiovascular disease; LDL, low-density lipoprotein; SAA, serum amyloid A; OxPL, oxidized phospholipids
Graphical Abstract The great complexity of HDL. High-density lipoprotein (HDL) particles carry a large number of proteins and lipids, which contribute to define their compositional and functional complexity. HDLs exert multiple protective activities, essentially by three major mechanisms. HDLs, however, can lose their protective functions and even gain adverse functions in chronic diseases or during infections. U-shaped relationships between HDL-cholesterol (HDL-C) levels and several conditions have been reported, being both low and extremely high HDL-C levels associated with an increased risk of several pathologies and mortality. LCAT, lecithin:cholesterol acyltransferase; CETP, cholesteryl ester transfer protein; PONI, paraoxonase 1; S1P, sphingosine-1-phosphate; ASCVD, atherosclerotic cardiovascular disease; LDL, low-density lipoprotein; SAA, serum amyloid A; OxPL, oxidized phospholipidsCC BY-NC · PubMed Central
Figure 1 High and low abundant lipids and proteins in high-density lipoprotein particles. Apo, apolipoprotein; LCAT, lecithin:cholesterol acyltransferase; CETP, cholesteryl ester transfer protein; PONI, paraoxonase 1; S1P, sphingosine-1-phosphate.
Figure 1 High and low abundant lipids and proteins in high-density lipoprotein particles. Apo, apolipoprotein; LCAT, lecithin:cholesterol acyltransferase; CETP, cholesteryl ester transfer protein; PONI, paraoxonase 1; S1P, sphingosine-1-phosphate.CC BY-NC · PubMed Central
Figure 2 Cholesterol transfers between high-density lipoprotein, very-low-density lipoprotein, low-density lipoprotein, and cells. ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; FC, free cholesterol, unesterified cholesterol; HDL, high-density lipoprotein; HL, hepatic lipase; LCAT, lecithin:cholesterol acyltransferase; LDL, low-density lipoprotein; LPL, lipoprotein lipase; PLTP, phospholipid transfer protein; SR-B1, scavenger receptor B1.
Figure 2 Cholesterol transfers between high-density lipoprotein, very-low-density lipoprotein, low-density lipoprotein, and cells. ABCA1, ATP-binding cassette transporter A1; ABCG1, ATP-binding cassette transporter G1; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; FC, free cholesterol, unesterified cholesterol; HDL, high-density lipoprotein; HL, hepatic lipase; LCAT, lecithin:cholesterol acyltransferase; LDL, low-density lipoprotein; LPL, lipoprotein lipase; PLTP, phospholipid transfer protein; SR-B1, scavenger receptor B1.CC BY-NC · PubMed Central
Figure 3 Structure–function relationships of high-density lipoprotein in health and disease. RNA, ribonucleic acid.
Figure 3 Structure–function relationships of high-density lipoprotein in health and disease. RNA, ribonucleic acid.CC BY-NC · PubMed Central
Figure 4 Lipoprotein-cholesterol as a function of increasing levels of non-fasting triglycerides. Based on 60 000 individuals from the Copenhagen General Population Study. CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; TG, triglycerides. Adapted from Chapman et al.99
Figure 4 Lipoprotein-cholesterol as a function of increasing levels of non-fasting triglycerides. Based on 60 000 individuals from the Copenhagen General Population Study. CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; TG, triglycerides. Adapted from Chapman et al.99CC BY-NC · PubMed Central
Figure 5 High-density lipoprotein levels on a continuous scale and risk of all-cause mortality in men and women from the Copenhagen General Population Study. Adapted from Madsen et al.30
Figure 5 High-density lipoprotein levels on a continuous scale and risk of all-cause mortality in men and women from the Copenhagen General Population Study. Adapted from Madsen et al.30CC BY-NC · PubMed Central
Figure 6 High-density lipoprotein levels on a continuous scale and risk of infectious disease, autoimmune disease, and cancer in individuals from the Copenhagen General Population Study. Adapted from Madsen et al.31 and Pedersen et al.120
Figure 6 High-density lipoprotein levels on a continuous scale and risk of infectious disease, autoimmune disease, and cancer in individuals from the Copenhagen General Population Study. Adapted from Madsen et al.31 and Pedersen et al.120CC BY-NC · PubMed Central
Figure 7 Estimated benefit and harm due to genetically lower non-high-density lipoprotein-cholesterol and genetically higher high-density lipoprotein-cholesterol due to inhibition of cholesteryl ester transfer protein. Based on individuals in the Copenhagen General Population Study. Lower non-high-density lipoprotein-cholesterol by 0.44 mmol/L (17 mg/dL) and higher high-density lipoprotein-cholesterol by 1.12 mmol/L (43 mg/dL) correspond to the changes observed through anacetrapib treatment compared with placebo in the REVEAL trial.9 AMD, age-related macular degeneration; HDL, high-density lipoprotein; Δ=difference. Adapted from Nordestgaard et al.144
Figure 7 Estimated benefit and harm due to genetically lower non-high-density lipoprotein-cholesterol and genetically higher high-density lipoprotein-cholesterol due to inhibition of cholesteryl ester transfer protein. Based on individuals in the Copenhagen General Population Study. Lower non-high-density lipoprotein-cholesterol by 0.44 mmol/L (17 mg/dL) and higher high-density lipoprotein-cholesterol by 1.12 mmol/L (43 mg/dL) correspond to the changes observed through anacetrapib treatment compared with placebo in the REVEAL trial.9 AMD, age-related macular degeneration; HDL, high-density lipoprotein; Δ=difference. Adapted from Nordestgaard et al.144CC BY-NC · PubMed Central
Figure 8 Examples of relative mass distribution of different lipoprotein fractions in different invertebrate and vertebrate species. HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein. Values adapted from Chapman145 and Van der Horst and Rodenburg.147
Figure 8 Examples of relative mass distribution of different lipoprotein fractions in different invertebrate and vertebrate species. HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-low-density lipoprotein. Values adapted from Chapman145 and Van der Horst and Rodenburg.147CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 179 references

Cited by

See all 459

Metadata

Authors
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L.
Affiliations
  • Institute of Clinical Chemistry, University Hospital Zurich and University of Zurich , Zurich , Switzerland
  • University of Copenhagen (DK)
  • National Institutes of Health (US)
  • University of Milan (IT)
Corresponding author
Catapano, Alberico L
Venue
European Heart Journal
Published
2022-11-07
Volume
44
Issue
16
Pages
1394-1407
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4308365150
Cited by
401
References
179
Citations by year
2026: 115 · 2025: 141 · 2024: 97 · 2023: 47 · 2022: 1
FWCI
17.04
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, cc-by-nc-nd)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, cc-by-nc)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Swiss National Science Foundation
  • Herlev and Gentofte Hospital
  • Copenhagen University Hospital
  • Italian Ministry of Health
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords
high-density lipoprotein, HDL cholesterol, atherosclerotic cardiovascular disease, reverse cholesterol transport, cholesterol efflux capacity, HDL particle number, apolipoprotein B-containing lipoproteins, sepsis mortality, infectious disease risk, diabetes mellitus, chronic kidney disease, autoimmune disease, cancer risk, age-related macular degeneration, all-cause mortality
MeSH terms
Clinical Relevance, Animals, Cholesterol, Humans, Lipoproteins, Lipoproteins, HDL, Cholesterol, HDL, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High-density lipoprotein revisited: biological functions and clinical relevance. https://app.cochat.ai/papers/10.1093/eurheartj/ehac605
The paper
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023). High-density lipoprotein revisited: biological functions and clinical relevance. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac605

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.